NCT02272946View on ClinicalTrials.gov

Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2021

Study Completion Date

December 31, 2021

Conditions
HIVCardiovascular Disease
Interventions
DRUG

Canakinumab

150mg Canakinumab received subcutaneously

DRUG

Placebo

150mg Placebo received subcutaneously

Trial Locations (1)

94110

San Francisco General Hospital, San Francisco

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Priscilla Hsue, MD

OTHER

NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk | Biotech Hunter | Biotech Hunter